Cargando…

Use of modeling and simulation to predict the influence of triazole antifungal agents on the pharmacokinetics of zanubrutinib and acalabrutinib

Background: Bruton’s tyrosine kinase (BTK) inhibitors are commonly used in the targeted therapy of B-cell malignancies. It is reported that myelosuppression and fungal infections might occur during antitumor therapy of BTK inhibitors, therefore a combination therapy with triazole antifungals is usua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Lu, Li, Chao, Bai, Hao, Li, Lixian, Chen, Wanyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588929/ https://www.ncbi.nlm.nih.gov/pubmed/36299883 http://dx.doi.org/10.3389/fphar.2022.960186

Ejemplares similares

PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES
por: Shadman, M., et al.
Publicado: (2022)

A novel UHPLC‒MS/MS method for quantitative analysis of zanubrutinib in rat plasma: application to an in vivo interaction study between zanubrutinib and triazole antifungal
por: Tang, Peng-fei, et al.
Publicado: (2023)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB
por: Shadman, Mazyar, et al.
Publicado: (2023)

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib
por: Estupiñán, H. Yesid, et al.
Publicado: (2021)

Zanubrutinib-induced aseptic meningitis: a case report and literature review
por: Yang, Jinjun, et al.
Publicado: (2023)

P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
por: Skarbnik, Alan, et al.
Publicado: (2023)

Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent
por: Cass, Lindsey, et al.
Publicado: (2020)

P632: COMPARISON OF TREATMENT-EMERGENT ADVERSE EVENTS OF ACALABRUTINIB AND ZANUBRUTINIB IN CLINICAL TRIALS IN B-CELL MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Hwang, Steven, et al.
Publicado: (2023)

Novel 1, 2, 4-Triazoles as Antifungal Agents
por: Kazeminejad, Zahra, et al.
Publicado: (2022)

Design, Synthesis, and Biological Activity of New Triazole and Nitro-Triazole Derivatives as Antifungal Agents
por: Sadeghpour, Hossein, et al.
Publicado: (2017)

An update on the development of novel antifungal agents for eumycetoma
por: Chandler, David J., et al.
Publicado: (2023)

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment
por: Xu, Yan, et al.
Publicado: (2022)

Simultaneous development of zanubrutinib in the USA and China
por: Li, Guanqiao, et al.
Publicado: (2020)

In vivo Pharmacokinetic Drug-Drug Interaction Studies Between Fedratinib and Antifungal Agents Based on a Newly Developed and Validated UPLC/MS-MS Method
por: Tang, Congrong, et al.
Publicado: (2021)

Physiologically based pharmacokinetic modelling and simulation to predict the plasma concentration profile of schaftoside after oral administration of total flavonoids of Desmodium styracifolium
por: Li, Xue, et al.
Publicado: (2022)

In Vivo Biomarker Analysis of the Effects of Intranasally Dosed PC945, a Novel Antifungal Triazole, on Aspergillus fumigatus Infection in Immunocompromised Mice
por: Kimura, Genki, et al.
Publicado: (2017)

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid
por: Salinger, David H., et al.
Publicado: (2019)

First-in-human study to investigate the safety and pharmacokinetics of salvianolic acid A and pharmacokinetic simulation using a physiologically based pharmacokinetic model
por: Chen, Jinliang, et al.
Publicado: (2022)

Population Pharmacokinetics of Caspofungin and Dose Simulations in Heart Transplant Recipients
por: Wu, Zheng, et al.
Publicado: (2022)

Prediction of a Therapeutic Dose for Buagafuran, a Potent Anxiolytic Agent by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Starting from Pharmacokinetics in Rats and Human
por: Yang, Fen, et al.
Publicado: (2017)

A novel LC-MS/MS method for simultaneous estimation of acalabrutinib and its active metabolite acalabrutinib M(27) in human plasma and application to a human pharmacokinetic study
por: Valluri, Venkat Rao, et al.
Publicado: (2022)

1,2,3-Triazole-Containing Compounds as Anti–Lung Cancer Agents: Current Developments, Mechanisms of Action, and Structure–Activity Relationship
por: Liang, Ting, et al.
Publicado: (2021)

Contribution of Population Pharmacokinetics of Glycopeptides and Antifungals to Dosage Adaptation in Paediatric Onco-hematological Malignancies: A Review
por: Leroux, Stéphanie, et al.
Publicado: (2021)

Pharmacokinetics of Acetaminophen and Metformin Hydrochloride in Rats After Exposure to Simulated High Altitude Hypoxia
por: Zhu, Jun-bo, et al.
Publicado: (2021)

Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice
por: Gu, Yongchuan, et al.
Publicado: (2017)

Acalabrutinib: Disseminated aspergillosis: case report
Publicado: (2022)

Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

Pharmacokinetics and Main Metabolites of Anwulignan in Mice
por: Chen, Cong, et al.
Publicado: (2022)

Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series
por: Zhang, Yan, et al.
Publicado: (2021)

Adverse Effects Associated With Currently Commonly Used Antifungal Agents: A Network Meta-Analysis and Systematic Review
por: Yang, Yan-Li, et al.
Publicado: (2021)

Prediction of histone deacetylase inhibition by triazole compounds based on artificial intelligence
por: Wang, Yiran, et al.
Publicado: (2023)

A Promising Anticancer Agent Dimethoxycurcumin: Aspects of Pharmacokinetics, Efficacy, Mechanism, and Nanoformulation for Drug Delivery
por: Sohail, Muhammad, et al.
Publicado: (2021)

Synthesis and Evaluation of Baylis-Hillman Reaction Derived Imidazole and Triazole Cinnamates as Antifungal Agents
por: Nelson, Grady L., et al.
Publicado: (2018)

Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies
por: Ou, Ying C., et al.
Publicado: (2021)

Microfluidic technology and simulation models in studying pharmacokinetics during pregnancy
por: Kammala, Ananth K., et al.
Publicado: (2023)

An ultrasound assisted, ionic liquid-molecular iodine synergy driven efficient green synthesis of pyrrolobenzodiazepine-triazole hybrids as potential anticancer agents
por: Saquib, Mohammad, et al.
Publicado: (2023)

The importance of pharmacokinetics and pharmacodynamics in antimicrobial drug development and their influence on the success of agents developed to combat resistant gram negative pathogens: A review
por: Palmer, Mary E., et al.
Publicado: (2022)

Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis
por: Wring, Stephen A., et al.
Publicado: (2017)

Pharmacokinetics and Disposition of Heparin-Binding Growth Factor Midkine Antisense Oligonucleotide Nanoliposomes in Experimental Animal Species and Prediction of Human Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model
por: Bai, Haihong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qnbqk8f6rfmsqhtbo8b06jj0h6